Document 0084
 DOCN  M9650084
 TI    HIV and intermediate immune deficiency.
 DT    9605
 AU    Adelstein S; McKnight I; Pethebridge AM; Department of Clinical
       Immunology, Royal Prince Alfred Hospital,; Sydney, NSW.
 SO    Med J Aust. 1996 Jan 15;164(2):109-10. Unique Identifier : AIDSLINE
       MED/96158829
 AB    Intermediate immune deficiency is defined by a CD4 cell count between
       500/microL and 200/microL. This phase is one of increasing therapeutic
       intervention, mostly for minor infections of skin and mucous membranes
       and mostly manageable within general practice. Most people with HIV
       begin antiretroviral therapy during this phase. Regular monitoring of
       CD4 cell count is essential for making appropriate therapeutic decisions
       and for determining prognosis.
 DE    Adult  Antiviral Agents/THERAPEUTIC USE  *Clinical Medicine  CD4
       Lymphocyte Count  Human  HIV Infections/IMMUNOLOGY/*THERAPY  Middle Age
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).